SCHEMBL141346

SCHEMBL141346

CCc1cc(CCC(=O)O)c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4)cc32)[nH]1

nearest known ligand 0.64

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 10/20 0.64
▸ FLT1 P17948 1/20 0.55
▸ SRC P12931 3/20 0.54
▸ PRKDC P78527 1/20 0.54
▸ FGFR1 P11362 6/20 0.53
▸ KDR P35968 6/20 0.53
▸ PDGFRB P09619 5/20 0.53
▸ EGFR P00533 2/20 0.51
▸ AURKB Q96GD4 4/20 0.48
▸ ZAP70 P43403 2/20 0.47
▸ FYN P06241 1/20 0.46
▸ YES1 P07947 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144702 0.84 PDGFRB (0.76) AURKAFLT1SRCFGFR1KDR
SCHEMBL147260 0.82 FGFR1 (0.76) AURKAFLT1SRCPRKDCFGFR1
SCHEMBL6326012 0.81 AURKA (0.68) AURKAFLT1SRCPRKDCFGFR1
SCHEMBL6331049 0.79 AURKA (0.66) AURKAFLT1SRCPRKDCFGFR1
SCHEMBL144608 0.79 AURKA (0.63) AURKAFLT1SRCPRKDCFGFR1
SCHEMBL3793305 0.78 AURKA (1.00) AURKAFGFR1KDRPDGFRBAURKB
SCHEMBL3793310 0.78 AURKA (1.00) AURKAFGFR1KDRPDGFRBAURKB
SCHEMBL6335062 0.78 AURKA (0.64) AURKAFLT1SRCPRKDCFGFR1
SCHEMBL6331096 0.77 AURKA (0.62) AURKAFLT1SRCPRKDCFGFR1
SCHEMBL6519857 0.77 AURKA (0.56) AURKAFLT1SRCPRKDCFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 — — US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 — — US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 — — US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 — — US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 — — US disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 — — US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 — — US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 AURKA 4579/4885FLT1 565/4885SRC 2611/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 AURKA 4579/4885FLT1 565/4885SRC 2611/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 AURKA 273/4885FLT1 661/4885SRC 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback